Argent BioPharma Limited

OTCPK:RGTL.F Stock Report

Market Cap: US$8.8m

Argent BioPharma Management

Management criteria checks 3/4

Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is A$417.06K, comprised of 92.8% salary and 7.2% bonuses, including company stock and options. directly owns 17.12% of the company’s shares, worth $1.51M. The average tenure of the management team and the board of directors is 2.1 years and 3.9 years respectively.

Key information

Roby Zomer

Chief executive officer

AU$417.1k

Total compensation

CEO salary percentage92.8%
CEO tenure8.8yrs
CEO ownership17.1%
Management average tenure2.1yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to Argent BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$417kAU$387k

-AU$18m

Mar 31 2024n/an/a

-AU$17m

Dec 31 2023n/an/a

-AU$17m

Sep 30 2023n/an/a

-AU$19m

Jun 30 2023AU$354kAU$354k

-AU$21m

Mar 31 2023n/an/a

-AU$22m

Dec 31 2022n/an/a

-AU$23m

Sep 30 2022n/an/a

-AU$22m

Jun 30 2022AU$629kAU$422k

-AU$20m

Mar 31 2022n/an/a

-AU$19m

Dec 31 2021n/an/a

-AU$18m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021AU$481kAU$281k

-AU$16m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$16m

Jun 30 2020AU$440kAU$290k

-AU$19m

Dec 31 2019n/an/a

-AU$18m

Sep 30 2019n/an/a

-AU$14m

Jun 30 2019AU$495kAU$330k

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$498kAU$334k

-AU$8m

Compensation vs Market: Roby's total compensation ($USD271.03K) is below average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Roby's compensation has increased whilst the company is unprofitable.

CEO

Roby Zomer (44 yo)

8.8yrs

Tenure

AU$417,064

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Leadership Team

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.8yrsAU$417.06k17.12%
$ 1.5m
Igor Bluvstein
Chief Financial Officerless than a yearno datano data
Yifat Steuer
Deputy CEO & COO2.1yrsno data2.06%
$ 181.5k
Shachar Shimony
Group General Counselno datano datano data
Masa Oblak
People Managerno datano datano data
Amir Polak
Chief Pharmaceutical Development Officerno datano data1.09%
$ 96.3k
Sabina Suljakovic
Chief Quality and Commercial Officer4.2yrsno datano data
Nadya Lisovoder
Chief Medical Officerno datano datano data
Sasha Friedman
Deputy CEOno datano datano data
Yair Tal
Chief Information Security Officerno datano datano data
Rowan Harland
Company Secretary1.7yrsno datano data
Ana Oblak
Group Financial Controllerno datano datano data

2.1yrs

Average Tenure

Experienced Management: RGTL.F's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.8yrsAU$417.06k17.12%
$ 1.5m
Ross Grant Walker
Chairman of Strategic Advisory Boardno dataAU$32.00kno data
Uri Kramer
Member of Strategic Advisory Board8.3yrsno datano data
Layton Mills
Independent Non-Executive Director1.4yrsAU$61.92kno data
Wendyl D'Souza
Member of Medical Advisory Board6.3yrsno datano data
Daniel Robinson
Non-Executive Directorless than a yearAU$41.92kno data
Shlomo Sadoun
Member of Advisory Boardless than a yearno datano data

3.9yrs

Average Tenure

Experienced Board: RGTL.F's board of directors are considered experienced (3.9 years average tenure).